Evidence map›Paper›PMID 38667802›Full record

ArticleMarine drugs2024

Cecilie Græsholt, Tore Brembu, Charlotte Volpe, Zdenka Bartosova, Manuel Serif, Per Winge, Marianne Nymark

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Progress and challenges in CRISPR/Cas applications in microalgae.Journal of microbiology (Seoul, Korea) · 2025
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Cecilie GræsholtDepartment of Biology, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Tore BrembuDepartment of Biology, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0001-5622-8037
Charlotte VolpeDepartment of Fisheries and New Biomarine Industry, SINTEF Ocean, 7010 Trondheim, Norway.ORCID 0000-0002-3905-5645
Zdenka BartosovaDepartment of Biology, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0001-5644-1903
Manuel SerifDepartment of Biology, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0002-0584-6748
Per WingeDepartment of Biology, Norwegian University of Science and Technology, 7491 Trondheim, Norway.ORCID 0000-0003-4380-1951
Marianne NymarkDepartment of Biology, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
Norwegian University of Science and Technology · NOSINTEF · NO

Funding

The Research Council of Norway 344103
6 · The paper itself

Abstract

Carotenoids are pigments that have a range of functions in human health. The carotenoid diatoxanthin is suggested to have antioxidant, anti-inflammatory and chemo-preventive properties. Diatoxanthin is only produced by a few groups of microalgae, where it functions in photoprotection. Its large-scale production in microalgae is currently not feasible. In fact, rapid conversion into the inactive pigment diadinoxanthin is triggered when cells are removed from a high-intensity light source, which is the case during large-scale harvesting of microalgae biomass. Zeaxanthin epoxidase (ZEP) 2 and/or ZEP3 have been suggested to be responsible for the back-conversion of high-light accumulated diatoxanthin to diadinoxanthin in low-light in diatoms. Using CRISPR/Cas9 gene editing technology, we knocked out the

Indexed as

DiatomsOxidoreductasesXanthophyllsCarotenoidsCRISPR-Cas SystemsGene Knockout TechniquesMicroalgaeMutationCarotenoidsdiadinoxanthindiatoxanthinOxidoreductasesXanthophyllszeaxanthin epoxidasebioactive carotenoidcommercial production lineCRISPR/Cas9 gene editingdiatoxanthinPhaeodactylum tricornutumzeaxanthin epoxidase

Identifiers

PMID38667802
PMCPMC11051370
OpenAlexW4394952817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.